secwatch.observer — SEC 8-K summary
======================================

Issuer:     TALPHERA, INC. (TLPH)
CIK:        0001427925
Form:       8-K
Filed at:   2023-04-07T23:59:59+00:00
Accession:  0001437749-23-009746
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.02, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AcelRx closes sale of DSUVIA to Alora for up to $116.5M in milestones; repays Oxford loan
--------------------------------------------------------------------------------

- Closed divestment of DSUVIA to Alora Pharmaceuticals on April 3, 2023; received ~$2.7M from Aguettant and Alora at closing.
- Consideration includes $1.1M upfront, 15% royalty on commercial sales, 75% on DoD sales, and up to $116.5M in milestones.
- Fully repaid $5.4M Oxford loan with no prepayment penalties; company becomes debt-free after transaction.
- Pro forma financials reflect removal of DSUVIA-related revenues and expenses; focus shifts to Niyad and Fedsyra pipeline.
- Amended Aguettant agreements include €1.5M complementary payment and termination of certain sales milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427925/000143774923009746/0001437749-23-009746-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427925/000143774923009746/acrx20230406_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-009746

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer